Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant

NCT00386412 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00386412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00386412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
September 30, 2009
Enrollment
132 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infection